Deutsch
Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Deutsch
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Evolent Health
(NYSE:EVH)
Intraday
$28.32
0
[0.00%]
15 minutes delayed
Get Report
Watch
Perks
Buy
Compare Brokers
$28.32
0
[0.00%]
Last update: 4:20PM
Get Real Time Here
Get Report
Watch
Q1 2024 Earnings in 13 days from now on Thu May 9th, after the market close
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for Evolent Health Stock (NYSE:EVH)
Evolent Health Stock (NYSE: EVH)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Monday, April 22, 2024
In-Depth Examination Of 6 Analyst Recommendations For Evolent Health
Benzinga Insights
-
3 days ago
Citigroup Initiates Coverage On Evolent Health with Buy Rating, Announces Price Target of $40
Benzinga Newsdesk
-
4 days ago
Thursday, March 28, 2024
Canaccord Genuity Maintains Buy on Evolent Health, Lowers Price Target to $44
Benzinga Newsdesk
-
Mar 28, 2024, 7:27AM
Friday, March 15, 2024
Navigating 4 Analyst Ratings For Evolent Health
Benzinga Insights
-
Mar 15, 2024, 12:00PM
JP Morgan Maintains Overweight on Evolent Health, Lowers Price Target to $52
Benzinga Newsdesk
-
Mar 15, 2024, 10:17AM
Friday, March 01, 2024
Oppenheimer Initiates Coverage On Evolent Health with Outperform Rating, Announces Price Target of $45
Benzinga Newsdesk
-
Mar 1, 2024, 7:59AM
Friday, February 23, 2024
These Analysts Revise Their Forecasts On Evolent Health After Upbeat Results
Avi Kapoor
-
Feb 23, 2024, 2:31PM
Why MercadoLibre Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Avi Kapoor
-
Feb 23, 2024, 2:07PM
Analyst Scoreboard: 4 Ratings For Evolent Health
Benzinga Insights
-
Feb 23, 2024, 1:01PM
JMP Securities Maintains Market Outperform on Evolent Health, Raises Price Target to $38
Benzinga Newsdesk
-
Feb 23, 2024, 12:34PM
Canaccord Genuity Maintains Buy on Evolent Health, Lowers Price Target to $45
Benzinga Newsdesk
-
Feb 23, 2024, 9:40AM
Evolent Health shares are trading higher after the company reported better-than-expected Q4 financial results.
Benzinga Newsdesk
-
Feb 23, 2024, 8:40AM
Thursday, February 22, 2024
Evolent Health Q4 EPS $0.23 Beats $0.15 Estimate, Sales $556.05M Beat $542.39M Estimate
Happy Mohamed
-
Feb 22, 2024, 4:45PM
Evolent Health Q4 Sales $556.05M Beat $542.40M Estimate
Benzinga Newsdesk
-
Feb 22, 2024, 4:36PM
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga Insights
-
Feb 22, 2024, 4:31PM
Earnings Scheduled For February 22, 2024
Benzinga Insights
-
Feb 22, 2024, 5:27AM
Wednesday, February 21, 2024
Evolent Health's Earnings: A Preview
Benzinga Insights
-
Feb 21, 2024, 10:01AM
Wednesday, December 06, 2023
Analyst Expectations for Evolent Health's Future
Benzinga Insights
-
Dec 6, 2023, 8:00AM
JMP Securities Initiates Coverage On Evolent Health with Market Outperform Rating, Announces Price Target of $37
Benzinga Newsdesk
-
Dec 6, 2023, 5:51AM
Evolent Health Prices $350M 3.50% Convertible Senior Notes Due 2029 To Pay Down Senior Term Loan
Benzinga Newsdesk
-
Dec 6, 2023, 2:42AM
Tuesday, December 05, 2023
Why Daktronics Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Lisa Levin
-
Dec 5, 2023, 1:06PM
Evolent Health shares are trading lower after the company announced a proposed offering of $350M of convertible senior notes due 2029.
Benzinga Newsdesk
-
Dec 5, 2023, 10:53AM
Evolent Health Announces Proposed Offering Of $350M Of Convertible Senior Notes Due 2029 To Pay Down Senior Term Loan
Benzinga Newsdesk
-
Dec 5, 2023, 7:01AM
Tuesday, November 28, 2023
RBC Capital Maintains Outperform on Evolent Health, Lowers Price Target to $42
Benzinga Newsdesk
-
Nov 28, 2023, 11:00AM
Tuesday, November 14, 2023
Truist Securities Maintains Hold on Evolent Health, Lowers Price Target to $34-Report Released on 13th Nov 2023
Benzinga Newsdesk
-
Nov 14, 2023, 10:50AM
Truist Securities Maintains Hold on Evolent Health, Lowers Price Target to $34
Benzinga Newsdesk
-
Nov 14, 2023, 10:48AM
Friday, November 03, 2023
Evolent Health shares are trading higher after the company reported better-than-expected Q3 sales results and issued guidance.
Benzinga Newsdesk
-
Nov 3, 2023, 12:50PM
Expedia Group, Gartner, Cloudflare, Cardinal Health And Other Big Stocks Moving Higher On Friday
Lisa Levin
-
Nov 3, 2023, 11:30AM
Thursday, November 02, 2023
Evolent Health Sees FY23 Revenue $1.945B-$1.965B Vs $1.95B Est.
Benzinga Newsdesk
-
Nov 2, 2023, 5:23PM
Evolent Health Sees Q4 2023 Revenue $537M-$557M Vs $545.42M Estimate
Benzinga Newsdesk
-
Nov 2, 2023, 5:22PM
Evolent Health Q3 2023 Revenue $511M Beats $509.239M Estimate
Benzinga Newsdesk
-
Nov 2, 2023, 4:35PM
Earnings Scheduled For November 2, 2023
Benzinga Insights
-
Nov 2, 2023, 4:56AM
Monday, October 16, 2023
Benzinga's Top Ratings Upgrades, Downgrades For October 16, 2023
Benzinga Insights
-
Oct 16, 2023, 11:00AM
UBS Initiates Coverage On Evolent Health with Buy Rating, Announces Price Target of $46
Benzinga Newsdesk
-
Oct 16, 2023, 8:42AM
Friday, September 22, 2023
30 US States Pause Medicaid Disenrollment Due To Technical Glitch
Vandana Singh
-
Sep 22, 2023, 7:56AM
Monday, August 14, 2023
Guggenheim Reiterates Buy on Evolent Health, Maintains $47 Price Target
Benzinga Newsdesk
-
Aug 14, 2023, 8:33AM
Friday, August 04, 2023
Evolent Health shares are trading higher following a Q2 earnings beat.
Benzinga Newsdesk
-
Aug 4, 2023, 1:00PM
Wednesday, August 02, 2023
Evolent Health Says We Do Not Believe We Can Meaningfully Reconcile Guidance For Non-GAAP Adjusted EBITDA To Net Income (Loss) Attributable To Common Shareholders
Benzinga Newsdesk
-
Aug 2, 2023, 4:33PM
Evolent Health Q2 Adj $0.14 Beats $0.09 Estimate, Sales $469.14M Beat $462.51M Estimate
Benzinga Newsdesk
-
Aug 2, 2023, 4:31PM
Earnings Scheduled For August 2, 2023
Benzinga Insights
-
Aug 2, 2023, 8:45AM
Tuesday, August 01, 2023
Earnings Outlook For Evolent Health
Benzinga Insights
-
Aug 1, 2023, 12:02PM
Monday, June 26, 2023
Analyst Ratings for Evolent Health
Benzinga Insights
-
Jun 26, 2023, 4:01PM
Wednesday, May 24, 2023
RBC Capital Reiterates Outperform on Evolent Health, Maintains $44 Price Target
Benzinga Newsdesk
-
May 24, 2023, 9:31AM
Thursday, May 04, 2023
Evolent Health shares are trading lower after the company reported worse-than-expected Q1 sales results.
Benzinga Newsdesk
-
May 4, 2023, 10:14AM
Stephens & Co. Reiterates Overweight on Evolent Health, Maintains $40 Price Target
Benzinga Newsdesk
-
May 4, 2023, 8:27AM
Wednesday, May 03, 2023
Recap: Evolent Health Q1 Earnings
Benzinga Insights
-
May 3, 2023, 4:44PM
Evolent Health Sees Q2 Revenue $455M-$470M vs $464.93M Est.; Sees FY23 Revenue $1.935B-$1.965B vs $1.94B Est.
Benzinga Newsdesk
-
May 3, 2023, 4:14PM
Evolent Health Q1 EPS $0.20, Inline, Sales $427.70M Miss $434.34M Estimate
Benzinga Newsdesk
-
May 3, 2023, 4:12PM
Wednesday, April 12, 2023
Benzinga's Top Ratings Upgrades, Downgrades For April 12, 2023
Benzinga Insights
-
Apr 12, 2023, 11:00AM
Stephens & Co. Initiates Coverage On Evolent Health with Overweight Rating, Announces Price Target of $40
Benzinga Newsdesk
-
Apr 12, 2023, 8:22AM
Show more
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch